Why the study?
Does sildenafil improve clinical and haemodynamical outcomes in a patient with end-stage hypertrophic cardiomyopathy and postcapillary pulmonary hypertension?
Does sildenafil improve clinical and haemodynamical outcomes in a patient with end-stage hypertrophic cardiomyopathy and postcapillary pulmonary hypertension?
Sildenafil may offer clinical and hemodynamic benefits in patients with end-stage hypertrophic cardiomyopathy complicated by postcapillary pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
May support sildenafil in end-stage hypertrophic cardiomyopathy with postcapillary pulmonary hypertension; hypothesis-generating, needs prospective trials.
Hypertrophic cardiomyopathy (HCM) is the most common inheritable cardiac disorder with an estimated prevalence of 1:500 in the general population. In minority of patients, with the prevalence approximately of 3–5%, HCM progresses into dilated, end-stage or burn-out phase, characterized by LV wall thinning, systolic dysfunction and LV cavity dilatation. We present a case of a 45 year-old man with endstage HCM with postcapillary pulmonary hypertension, who was experimentally treated with sildenafil. It resulted in noticeable clinical and haemodynamical improvement. JRCD 2014; 2 (1): 23–26
No takes yet. Share an insight, caveat, or question.
Wiśniowska‐Śmiałek et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: